Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. This is the online version of STAT’s weekly…
In a highly unusual move, a small biotech company has disclosed a rejection letter from the Food and Drug Administration in hopes of rallying support for regulatory approval of an ultra-rare disease drug. The step is part of a campaign being pursued by Stealth BioTherapeutics in light of its seesaw experience with the agency over…
The top executives running the health care industry’s blue-chip companies amassed generational wealth in 2024, even as many businesses slipped in the eyes of their investors. Health care remains a highly profitable industry. But the biggest companies didn’t meet the lofty expectations of shareholders, dragging down their stocks. A few CEOs lost their jobs as…
Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators on Friday to treat an increasingly common liver disease, adding to the list of conditions for which the blockbuster therapy is now approved. The Food and Drug Administration granted accelerated approval to Wegovy for patients with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate to advanced…
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which…
WASHINGTON — Eli Lilly said Thursday that it would increase the prices of medicines in Europe and other developed markets “in order to make them lower” in the U.S., in an apparent response to the Trump administration’s calls to do so. It singled out the list price of its popular weight-loss drug in the U.K. as…
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Season two of the hospital drama “The Pitt” will include storylines that envision how Medicaid cuts in Republicans’ One Big Beautiful Bill will impact…
In an unexpected move, the Trump administration signaled recently that it may rely on a controversial federal law to sidestep Harvard University patents that emerged with the help of U.S. government funding. At issue is a provision of the Bayh-Dole Act, which was enacted 45 years ago to enable universities, nonprofits, and small businesses to…
WASHINGTON — A handful of drug companies have formed a group to present lawmakers with research on what the industry sees as the negative impacts of Medicare drug price negotiations, according to lobbying records. The group is called the IRA Watchdog after the Inflation Reduction Act, which directed Medicare to negotiate the prices for some…
University of Houston optometry researcher provides new hope for injured corneas: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link